1. Home
  2. RPD vs TECX Comparison

RPD vs TECX Comparison

Compare RPD & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rapid7 Inc.

RPD

Rapid7 Inc.

N/A

Current Price

$11.81

Market Cap

746.5M

Sector

Technology

ML Signal

N/A

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

N/A

Current Price

$37.52

Market Cap

618.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
RPD
TECX
Founded
2000
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
746.5M
618.9M
IPO Year
2015
2018

Fundamental Metrics

Financial Performance
Metric
RPD
TECX
Price
$11.81
$37.52
Analyst Decision
Hold
Strong Buy
Analyst Count
23
5
Target Price
$15.05
$75.20
AVG Volume (30 Days)
2.3M
179.1K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
40.70
EPS
0.11
N/A
Revenue
$685,083,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.54
N/A
P/E Ratio
$107.68
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.97
$14.39
52 Week High
$21.26
$39.53

Technical Indicators

Market Signals
Indicator
RPD
TECX
Relative Strength Index (RSI) 53.30 63.08
Support Level $5.86 $27.30
Resistance Level $14.27 $39.53
Average True Range (ATR) 0.96 2.25
MACD -0.06 0.67
Stochastic Oscillator 35.79 94.20

Price Performance

Historical Comparison
RPD
TECX

About RPD Rapid7 Inc.

Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: